Balti miltai, MB - financials and debts

Company age: 3 y. 1 mo.

Update

Balti miltai - Company finances

EUR
2023
From: 2023-08-22
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 891 41,524 23,215
Profit before tax -1,554 3,770 -610
Net profit -1,554 3,648 -610
Equity -1,544 2,104 8,811
Liabilities 13,449 10,017 53
Non-current assets 0 0 0
Current assets 11,905 12,121 8,864
Total assets 11,905 12,121 8,864
Taxes paid
STI taxes - 1,491 338
Financial indicators
Revenue change y/y - +4560.4% -44.1%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. -13.1% 30.1% -6.9%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. - 173.4% -6.9%
Profit margin Net profit margin. Shows the overall profitability of the company. -174.4% 8.8% -2.6%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. -174.4% 9.1% -2.6%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - 4.8 0.0
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Balti miltai - Social security debts

The company had no debts to Sodra

Balti miltai - VMI tax arrears

From To Overdue, €
2025-06-19 2025-06-30 122.04
2025-03-06 2025-06-18 0.04
2025-03-02 2025-03-04 23.89
2025-02-19 2025-03-01 23.79
2025-02-18 2025-02-18 23.78
2025-02-16 2025-02-17 23.75
2025-02-15 2025-02-15 23.61
2025-02-14 2025-02-14 23.0

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Balti miltai, MB (code 306386202) is a Lithuanian small partnership engaged in the retail sale of pharmaceutical products. In the latest financial year, 2025, the company generated revenue of €23.2K and posted a net loss of €610, corresponding to a net margin of -2.6%. Performance weakened from 2024, when revenue reached €41.5K and net profit was €3.6K, after a very small 2023 base of €891 revenue and a net loss of €1.6K. Over the two-year period, the business therefore moved from a minimal turnover level to substantially higher sales, although 2025 was below the prior year. The balance sheet at the end of 2025 was very conservatively financed: total assets were €8.9K, equity €8.8K and liabilities only €53, which resulted in an equity ratio of 99.4% and a debt-to-equity ratio of 0.01. Return on equity and return on assets were both -6.9%, while asset turnover stood at 2.62x. The 2025 figures indicate a small asset base, minimal leverage and a return to a modest loss after a profitable 2024.